Offline
| Post a Message | Explore Forums | Browse Stock Messages | Hot Discussions | Top rated Messages | Top Boarders | |
|
|
|
Orchid Chemicals and Pharmaceuticals
| ||||
Orchid down target=150....
Posted by :
venkatagopalTracked by: 0 Boarder
Hi marketman,
Earlier after selling by a fund left and right, the banks also have sold the stock which was pldged by the promoter. That brought the price to 106/- levels. I guess now that now it is turn of poonewala`s stock which might be pledged to Banks triggered the margin level for selling in bulk. Again 120/- 125/- levels are great chance for longterm investors.
Keep posting ur observations.
..venkat...
In reply to:
Orchid down target=150....
Posted by : marketman
Yes gopal,the target is achieved so soon.... it loks like that both poonawala and ranbaxy started exiting from the counter.... it may be a good chance for the rghavender to increase his stake further.... but is he having money to do for that?! 
Orchid down target=150....
Posted by : marketmanTracked by: 0 Boarder
Yes gopal,the target is achieved so soon.... it loks like that both poonawala and ranbaxy started exiting from the counter.... it may be a good chance for the rghavender to increase his stake further.... but is he having money to do for that?!...
In reply to:
Orchid down target=150....
Posted by : venkatagopal
Hi marketman,
You are rightly predicted. The stock is in lower circuit. Exit of Ranbaxy is really good news to Orchid lover.
The stock has not taken the market weakness till yesterday much.
Now it is reacting to reality. This may be one of the reasons for the stock cutting down.
I see a great opportunity if the stock lises another 10%.
Happy investing.
..venkat
Orchid down target=150....
Posted by : venkatagopalTracked by: 0 Boarder
Hi marketman,
You are rightly predicted. The stock is in lower circuit. Exit of Ranbaxy is really good news to Orchid lover.
The stock has not taken the market weakness till yesterday much.
Now it is reacting to reality. This may be one of the reasons for the stock cutting down.
I see a great opportunity if the stock lises another 10%.
Happy investing.
..venkat...
In reply to:
Orchid down target=150....
Posted by : marketman
The scrip of orchid is looking weak and may fall to 150 in coming days.... there is a talk in the market that ranbaxy promoters not showing interest in the counter and may offload the stock which bought recently by their finance company....
BSE Announcements on Orchid Chemical
Posted by : MMB MessengerTracked by: 0 Boarder
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that Dr. Anzaghi Piergiorgio, Director has resigned from the Board of the Company effect from October 03, 2008....
NSE Announcements on Orchid Chemical
Posted by : MMB MessengerTracked by: 0 Boarder
Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange that "Dr Anzaghi Piergiorgio, Director has resigned from the Board of Orchid Chemicals & Pharmaceuticals Limited with effect from October 3, 2008"....
Orchid down target=150....
Posted by : marketmanTracked by: 0 Boarder
The scrip of orchid is looking weak and may fall to 150 in coming days.... there is a talk in the market that ranbaxy promoters not showing interest in the counter and may offload the stock which bought recently by their finance company.......
Orchid promoter raises stake to 23%
Posted by : day_traderTracked by: 0 Boarder
Orchid Chemicals and Pharmaceuticals promoter K Raghavendra Rao has scaled up his stake in the company by nearly 6% to 23% through conversion of warrants into equity shares.
Mr Rao has converted 50 lakh warrants into equal number of equity shares for Rs 90 crore. The conversion price was Rs 202 a share. The Orchid stock closed at Rs 212.05 on the Bombay Stock Exchange on Friday.
Confirming the development, an Orchid Chemicals spokesperson said: "Promoters have used the option to convert the shares and increased their stake in the company to around 23%."
Orchid had issued the warrants to promoters in March 2007 and the conversion deadline was August 31, 2008. Mr Rao lost Rs 75 crore in a margin call-induced sell-off on March 17 and his stake fell to 15.8%.
In April this year, Solrex Pharmaceuticals, a company backed by Ranbaxy Laboratories, bought around 14.7% in Orchid from the open market, prompting speculation of a takeover. The initial period of the ownership tussle between Mr Rao and Solrex ebbed after the two parties settled for a strategic partnership.
Sources close to the development said that Mr Rao raised the required funds for converting warrants from close friends and other financial institutions.
Also, with Japan`s Daiichi Sankyo set to take a controlling stake in Ranbaxy, Orchid`s promoters can relax. Orchid has also set up a subsidiary in Japan. The company, however, would stick to its original plan of following an independent strategy for its generics foray into Japan where it expects to become a leading player, sources said.
It is eyeing $100 million revenues from Japan in the next five years. Orchid could leverage Daiichi’s strengths to get a firm foot in the fast-growing generics market in Japan, analysts opined.
...
orchid
Posted by : zoombusinessTracked by: 0 Boarder
Orchid Chemicals and Merck have announced a strategic Research Collaboration and Licence Agreement focused on discovery, development and commercialization of novel agents for treatment of bacterial and fungal infections.
Orchid Research Laboratories, the wholly owned drug discovery subsidiary of Orchid, and Merck will work together to identify and develop novel anti-bacterial and anti-fungal compounds as clinically validated drug candidates.
Orchid will undertake discovery and candidate development through Phase IIa human clinical trials. Merck will conduct late stage clinical development and commercialization if regulatory approval is granted.
Under the terms of the agreement, Orchid will be paid an undisclosed upfront sum and would be eligible to receive payments totaling more than $100 million on achievement of various research and development (R&D) milestones.
The agreement contemplates Merck and Orchid working together on multiple targets and compounds, which will be evaluated against specific criteria for discovery and development.
Orchid is also eligible to receive significant royalties on worldwide Net Sales of any products commercialized under the agreement. We maintain a BUY on Orchid Chemicals, with a target price of Rs340.
Angel Broking -
...
Dont...Dont...Dont ever think to sell ...
Posted by :
sinhabp30Tracked by: 0 Boarder
Yes, there may be a blood bath today....never mind, we all investors have already lost 70% value of our stocks but selling at this juncture in panic would certainly keep you out of your future.....out of market. so dear collegues....dont ever think to sell yr holding.....it will rebound from 3600/3300 and that is very sure...trust in our economy and think the US bailout amount of 700 billions. The FII\\`s have invested 6 billion in Indian market but they are dictating our market...if we get 5% of that amount in our growing market...what would be then....the market may touch the sky and sensex may be near to 35000....so dont panic and be quite...watch the drama which is not going to last longer and sure we will get back our hard earned money. Think it seriously, be silent and do nothing...only watch silently….this is the mantras of this hour....
Agreement with MERCK of US
Posted by : rvk41Tracked by: 0 Boarder
Orchid Chemicals & Pharmaceuticals Ltd and US-based Merck & Co Inc will work together to develop new drugs to treat bacterial and fungal infections, Orchid Chemicals said on Monday.
Orchid will sell 15-20% stake in research unit
Orchid will receive an undisclosed upfront payment and could receive more than $100 million in milestone payments, Orchid said in a statement.
Orchid Chem expects $50-60 m from tazobactum
The Orchid Chemicals will also receive royalties on global sale of the drugs.
Orchid's research unit, Orchid Research Laboratories, will identify drug targets and develop them through to phase-II clinical trials. Merck will conduct late-stage clinical trials and sell the drugs after regulatory approvals, Orchid added.
Merck has been signing a spate of agreements with Orchid Chemicals including one with Ranbaxy Laboratories for new anti-infectives drugs in May and another with Piramal Healthcare to develop new cancer drugs last November.
Global drug firms, pressured by expiring patents and disappointing drug pipelines, are increasingly outsourcing more research to countries such as India and China to cut costs.
Other similar pacts include Jubilant Organosys' deal with Amgen and Piramal's second drug development deal with Eli Lilly, both for developing drugs in multiple therapeutic areas.
For Information,with regards
rvk41...
BSE Announcements on Orchid Chemical
Posted by : MMB MessengerTracked by: 0 Boarder
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE regarding a Press Release dated September 29, 2008 titled "Orchid & Merck & Co., Inc. collaborate to develop novel anti-infective drugs"...
NSE Announcements on Orchid Chemical
Posted by : MMB MessengerTracked by: 0 Boarder
Orchid Chemicals & Pharmaceuticals Ltd has informed the Exchange regarding a press release dated September 29, 2008, titled "Orchid & Merck & Co., Inc. collaborate to develop novel anti-infective drugs". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements)....
Orchid Chemical will get boost in Pharma
Posted by : rajbansalTracked by: 0 Boarder
Orchid is remarking and can be seen nearl in around 300 and a buying opportunity between 200-225...
Orchid is a sector performer....
Posted by : marketmanTracked by: 0 Boarder
What happened to poonavala.... it is said to be he acquired huge amout of shares at around 250 on the back drop of ranbaxy support/interest in the stock.... now ranbaxy itself is in big trouble and this share price struggling at 210....
Mean time, the promotors group increased their stake in the company....
So, there wont be any take over threat from any other company.... the stock could be a sector performer.... no special rises can be expected in he counter in the near term....
...
BSE Announcements on Orchid Chemical
Posted by : MMB MessengerTracked by: 0 Boarder
Orchid Chemicals & Pharmaceuticals Ltd has informed BSE that Industrial Development Bank of India has withdrawn the nomination of Shri. S Andi and instead appointed Shri. S Jeyakumar, General Manager, Infrastructure Corporate Group, Industrial Development Bank of India Ltd, Mumbai as its nominee on the Board of the Company with effect from September 08, 2008....
More from the Pharmaceuticals Sector
see moreBoarders tracking Orchid Chemical
News Updates on Orchid Chemical
Explore Moneycontrol
